Clinical Trial

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Study acronym: Pembro-FLASH
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-19; most recent amendment 2025-04-02.
Trial Details
NCT Number NCT06045195
Lead Sponsor University of Cologne
Conditions Hodgkin Lymphoma
Enrollment 40 participants
Start Date 2025-08
Primary Completion 2027-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-06